Pharmaceutical Company Pneuma Respiratory Raises $8.3M Series A Funding

Pneuma Respiratory, Inc., a Boone, NC-based breath-activated digital inhaler (BDI), raised $8.3m in Series A financing.

The backers were not disclosed.

The company intends to use the funds to develop improved therapeutic treatments for patients who suffer from asthma and COPD.

Led by Eric Hunter, CEO and Founder, Pneuma Respiratory has developed the PNEUMAHALER™ Breath Activated Digital Inhaler (BDI) which aims to solve the problems of existing metered dose, dry- powder, and soft-mist inhalers to improve the efficacy of currently available airway medications for asthma and COPD.

PNEUMAHALER BDI merges advanced droplet ejector technology with digitally controlled breath-actuation, and package it in a lightweight, pocket-sized device. The inhaled delivery system has integrated Bluetooth technology to provide feedback on drug delivery to patients, family members and health care providers.



Join the discussion